Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 2Thyroid Nodule 1Prostatic Neoplasms 1Multiple Pulmonary Nodules 1Hyperaldosteronism 1Carcinoma, Renal Cell 1Bone Cancer Metastatic 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1ACTH Syndrome, Ectopic 1

Interventions

Bevacizumab 35durvalumab 23atezolizumab 22Nivolumab 20lenvatinib 19tremelimumab 16Specimen Handling 14Magnetic Resonance Spectroscopy 12sintilimab 11pembrolizumab 9Ipilimumab 9tislelizumab 7Sorafenib 7cabozantinib 5X-Rays 5Immunoglobulin G 5Disulfides 5Cyclophosphamide 5regorafenib 4Radiotherapy 4Radiosurgery 4Radiation 4Oxaliplatin 4Immunotherapy 4Ethiodized Oil 4fludarabine 3donafenib 3Surgical Procedures, Operative 3Folfox protocol 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Radiofrequency Ablation × 90 days × Clear all
NCT05666271 2026-04-13

Radiofrequency Ablation for Hepatocellular Carcinoma Using Octopus MP Electrodes

Seoul National University Hospital

Active not recruiting
76 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03753659 2026-03-23

IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Completed
30 enrolled 10 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡